instruction:
In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".
question:
Paragraph: Dendritic cells are potent antigen-capture and -presenting cells that play a key role in the initiation and regulation of the adaptive immune response. This process of immune homeostasis, as maintained by dendritic cells, is susceptible to dysregulation by certain pathogens during chronic infections. Such dysregulation may lead to disease perpetuation with potentially severe systemic consequences. Here we discuss in detail how intracellular pathogens exploit dendritic cells and evade degradation by altering or evading autophagy. This novel mechanism explains in part the chronic, persistent nature observed in several immuno-inflammatory diseases, including periodontal disease. Also, here we propose a hypothetical model on the plausible role of autophagy in the context of periodontal disease. Promotion of autophagy may open new therapeutic strategies in the search for a "cure" for periodontal disease in humans. 
 Title: Dendritic cells: microbial clearance via autophagy and potential immunobiological consequences for periodontal disease
answer:
True


question:
Paragraph: Pulmonary arterial hypertension (PAH) is a chronic lung disease with poor diagnosis and limited therapeutic options. The currently available therapies are ineffective in improving the quality of life and reducing mortality rates. There exists a clear unmet medical need to treat this disease, which necessitates the discovery of novel therapeutic targets/agents for safe and successful therapy. An altered renin-angiotensin system (RAS) has been implicated as a causative factor in the pathogenesis of PAH. Angiotensin II (Ang II), a key effector peptide of the RAS, can exert deleterious effects on the pulmonary vasculature resulting in vasoconstriction, proliferation, and inflammation, all of which contribute to PAH development. Recently, a new member of the RAS, angiotensin converting enzyme 2 (ACE2), was discovered. This enzyme functions as a negative regulator of the angiotensin system by metabolizing Ang II to a putative protective peptide, angiotensin-(1-7). ACE2 is abundantly expressed in the lung tissue and emerging evidence suggests a beneficial role for this enzyme against lung diseases. In this review, we focus on ACE2 in relation to pulmonary hypertension and provide proof of principle for its therapeutic role in PAH. 
 Title: ACE2, a promising therapeutic target for pulmonary hypertension
answer:
False


question:
Paragraph: In order to determine the minimum RNase A concentration to degrade siRNA completely, siRNA (300 ng) was incubated with different amounts of RNase A in TE 1X pH 8 buffer (0.02, 0.07, 0.162, 0.348, 0.7, and 3.3 g RNase A per 1 g siRNA) for 45 min at 37C, in presence or absence of RiboLock ® RNase Inhibitor (RI, 1L = 40U). The concentration of 0.35 g RNase A per 1 g siRNA has been reported in literature to be enough to degrade a large fraction of siRNA in polyplexes, 1, 2 and based on that, the amount of RNase A was varied in this experiment. Next, samples were frozen at -20C overnight, and loaded in the slots of casted agarose gel (1.5 % w/v in TAE 1X pH 8.2 buffer) stained with ethidium bromide (0.5 g  mL -1 ). The electrophoresis was performed at 60V (E0160-VWR Mini Gel Electrophoresis) for 40 min, and the siRNA-dye migration was visualized under UV irradiation (FOTO/Analyst ® Investigator/Eclipse with UV Transilluminator Fotodyne Inc.) and the images were recorded using the FOTO/Analyst ® PC Image software (v.5). The result is shown in Figure S1 , and clearly indicates that free siRNA (not protected by RNase inhibitor) was completely degraded by RNAse A starting at concentration 0.162 g RNase A per 1 g siRNA, since no siRNA band was observed in lane 6 compared to lane 7 and lane 1. 
 Title: Poly(amidoamine) Dendrimer Nanocarriers and their Aerosol Formulations for siRNA Delivery to the Lung Epithelium
answer:

True